Objective:To summarize and compare the clinical characteristics of immune checkpoint inhibitor-associated pneumonia(CIP)in elderly and non-elderly lung cancer patients treated with immune checkpoint inhibitors(ICIs).Methods:We conducted a retrospective analysis of the clinical data from 61 patients who developed CIP following ICIs treatment in the Respiratory and Critical Care Medicine Department and the Oncology Department of Beijing Hospital from May 2016 to April 2024.The clinical characteristics of patients aged 65 years and older were compared with those of patients younger than 65 years.Results:A total of 61 patients were included in the study, with 26 patients in the group aged <65 years[aged 39-64(56.3±5.6)years].Within this group, the clinical grades were distributed as follows: 5 patients in grade 1(G1), 12 in grade 2(G2), 7 in grade 3(G3), and 2 in grade 4(G4).Twelve patients underwent bronchoscopy, while 17 patients received corticosteroid therapy after developing CIP.Additionally, 20 patients permanently discontinued immunotherapy due to CIP.Notably, one patient showed improvement in CIP following treatment, which allowed for the continuation of ICIs.Importantly, no patients in this group experienced mortality due to CIP.In the group aged ≥65 years[aged 65-83(71.9±4.9)years], there were 35 patients, categorized as follows: 4 in G1, 22 in G2, 5 in G3, and 4 in G4.Twenty-one patients underwent bronchoscopy, 31 received corticosteroid therapy after developing CIP, and 30 patients permanently discontinued immunotherapy due to CIP.Similarly, one patient in this group demonstrated improvement in CIP following treatment, which permitted the continuation of ICIs.Importantly, no patients in this group experienced mortality due to CIP.Compared to patients aged <65 years, those aged ≥65 years experienced a shorter median time to the occurrence of CIP, with a median of 2(1, 4)months versus 5.5(2, 8)months for the younger group( Z=-3.231, P=0.001).Furthermore, a higher proportion of patients aged ≥65 years received corticosteroid therapy after developing CIP(88.57% or 31 cases)compared to 65.38%(17 cases)in the younger group( χ2=4.704, P=0.030).There were no statistically significant differences in the occurrence of CIP symptoms or chest imaging characteristics between the two age groups(both P>0.05). Conclusions:Patients aged 65 years and older experience a shorter median time to develop CIP following the use of ICIs.However, there is no significant difference in clinical outcomes when compared to the group aged under 65 years, provided that early identification and diagnosis are achieved.

OBJECTIVES: To explore the expression profile of circular RNAs (circRNAs) and their potential roles in prognosis and progression of Wilms' tumor (WT). METHODS: Four pairs of WT and adjacent tissues were collected for high-throughput circRNA sequencing to identify the differentially expressed circular RNAs. RT-qPCR was used to verify the expression levels of the top 6 candidate circRNAs in the clinical samples. hsa_circ_0001900 was selected for analysis of its correlation with clinicopathological features and prognosis in 34 patients with WT. Sanger sequencing and RNase R digestion experiments were used to verify the cycling site and structural stability of hsa_circ_0001900 molecule. RESULTS: A total of 23 978 circular RNA molecules were identified in WT tissues by high-throughput circular RNA sequencing, and among them 614 were differentially expressed in WT. hsa_circ_0001900 showed the highest expression level among the differentially expressed circRNAs, which was consistent with the findings in clinical tumor samples and the sequencing results. Correlation analysis showed that hsa_circ_0001900 expression level was positively correlated with WT volume, and the children with high hsa_circ_0001900 expression had a lowered recurrence-free survival rate. The results of Sanger sequencing verified the circular splice site sequence of the molecule, and Rnase R digestion assay confirmed its stable covalent structure. CONCLUSIONS This study presents a comprehensive expression profile of circular RNAs in WT, and the expression level of hsa_circ_0001900 is related to the size of WT and the patients' prognosis, suggesting its possible role as a key driving gene in WT progression.
Humans ; RNA, Circular ; Wilms Tumor/pathology* ; Prognosis ; High-Throughput Nucleotide Sequencing ; Kidney Neoplasms/genetics* ; Sequence Analysis, RNA ; Male ; Female

Objective:To summarize and compare the clinical characteristics of immune checkpoint inhibitor-associated pneumonia(CIP)in elderly and non-elderly lung cancer patients treated with immune checkpoint inhibitors(ICIs).Methods:We conducted a retrospective analysis of the clinical data from 61 patients who developed CIP following ICIs treatment in the Respiratory and Critical Care Medicine Department and the Oncology Department of Beijing Hospital from May 2016 to April 2024.The clinical characteristics of patients aged 65 years and older were compared with those of patients younger than 65 years.Results:A total of 61 patients were included in the study, with 26 patients in the group aged <65 years[aged 39-64(56.3±5.6)years].Within this group, the clinical grades were distributed as follows: 5 patients in grade 1(G1), 12 in grade 2(G2), 7 in grade 3(G3), and 2 in grade 4(G4).Twelve patients underwent bronchoscopy, while 17 patients received corticosteroid therapy after developing CIP.Additionally, 20 patients permanently discontinued immunotherapy due to CIP.Notably, one patient showed improvement in CIP following treatment, which allowed for the continuation of ICIs.Importantly, no patients in this group experienced mortality due to CIP.In the group aged ≥65 years[aged 65-83(71.9±4.9)years], there were 35 patients, categorized as follows: 4 in G1, 22 in G2, 5 in G3, and 4 in G4.Twenty-one patients underwent bronchoscopy, 31 received corticosteroid therapy after developing CIP, and 30 patients permanently discontinued immunotherapy due to CIP.Similarly, one patient in this group demonstrated improvement in CIP following treatment, which permitted the continuation of ICIs.Importantly, no patients in this group experienced mortality due to CIP.Compared to patients aged <65 years, those aged ≥65 years experienced a shorter median time to the occurrence of CIP, with a median of 2(1, 4)months versus 5.5(2, 8)months for the younger group( Z=-3.231, P=0.001).Furthermore, a higher proportion of patients aged ≥65 years received corticosteroid therapy after developing CIP(88.57% or 31 cases)compared to 65.38%(17 cases)in the younger group( χ2=4.704, P=0.030).There were no statistically significant differences in the occurrence of CIP symptoms or chest imaging characteristics between the two age groups(both P>0.05). Conclusions:Patients aged 65 years and older experience a shorter median time to develop CIP following the use of ICIs.However, there is no significant difference in clinical outcomes when compared to the group aged under 65 years, provided that early identification and diagnosis are achieved.

Objective To identify the key genes differentially expressed in Wilms tumor and analyze their potential impacts on prognosis and immune responses of the patients. Methods High-throughput RNA sequencing was used to identify the differentially expressed mRNAs in clinical samples of Wilms tumor and paired normal tissues, and their biological functions were analyzed using GO, KEGG and GSEA enrichment analyses. The hub genes were identified using STRING database, based on which a prognostic model was constructed using LASSO regression. The mutations of the key hub genes were analyzed and their impacts on immunotherapy efficacy was predicted using the cBioPortal platform. RT-qPCR was used to verify the differential expressions of the key hub genes in Wilms tumor. Results Of the 1612 differentially expressed genes identified in Wilms tumor, 1030 were up-regulated and 582 were down-regulated, involving mainly cell cycle processes and immune responses. Ten hub genes were identified, among which 4 genes (TP53, MED1, CCNB1 and EGF) were closely related to the survival of children with Wilms tumor. A 3-gene prognostic signature was constructed through LASSO regression analysis, and the patients stratified into with high- and low-risk groups based on this signature had significantly different survival outcomes (HR=1.814, log-rank P=0.002). The AUCs of the 3-, 5-and 7-year survival ROC curves of this model were all greater than 0.7. The overall mutations in the key hub genes or the individual mutations in TP53/CCNB1 were strongly correlated with a lower survival rates, and a high TP53 expression was correlated with a poor immunotherapy efficacy. RT-qPCR confirmed that the key hub genes had significant differential expressions in Wilms tumor tissues and cells. Conclusion TP53 gene plays an important role in the Wilms tumor and may potentially serve as a new immunotherapeutic biomarker as well as a therapeutic target.

Objective To identify the key genes differentially expressed in Wilms tumor and analyze their potential impacts on prognosis and immune responses of the patients. Methods High-throughput RNA sequencing was used to identify the differentially expressed mRNAs in clinical samples of Wilms tumor and paired normal tissues, and their biological functions were analyzed using GO, KEGG and GSEA enrichment analyses. The hub genes were identified using STRING database, based on which a prognostic model was constructed using LASSO regression. The mutations of the key hub genes were analyzed and their impacts on immunotherapy efficacy was predicted using the cBioPortal platform. RT-qPCR was used to verify the differential expressions of the key hub genes in Wilms tumor. Results Of the 1612 differentially expressed genes identified in Wilms tumor, 1030 were up-regulated and 582 were down-regulated, involving mainly cell cycle processes and immune responses. Ten hub genes were identified, among which 4 genes (TP53, MED1, CCNB1 and EGF) were closely related to the survival of children with Wilms tumor. A 3-gene prognostic signature was constructed through LASSO regression analysis, and the patients stratified into with high- and low-risk groups based on this signature had significantly different survival outcomes (HR=1.814, log-rank P=0.002). The AUCs of the 3-, 5-and 7-year survival ROC curves of this model were all greater than 0.7. The overall mutations in the key hub genes or the individual mutations in TP53/CCNB1 were strongly correlated with a lower survival rates, and a high TP53 expression was correlated with a poor immunotherapy efficacy. RT-qPCR confirmed that the key hub genes had significant differential expressions in Wilms tumor tissues and cells. Conclusion TP53 gene plays an important role in the Wilms tumor and may potentially serve as a new immunotherapeutic biomarker as well as a therapeutic target.

Objective: To verify the safety and efficacy of IONTRIS particle therapy system (IONTRIS) in clinical implementation. Methods: Between 6.2014 and 8.2014, a total of 35 patients were enrolled into this trial: 31 males and 4 females with a median age of 69 yrs (range 39-80). Ten patients had locally recurrent head and neck tumors after surgery, 4 cases with thoracic malignancies, 1 case with hepatocellular carcinoma, 1 case with retroperitoneal sarcoma, and 19 cases with non-metastatic prostate carcinomas. Phantom dose verification was mandatory for each field before the start of radiation. Results: Twenty-two patients received carbon ion and 13 had proton irradiation. With a median follow-up time of 1 year, all patients were alive. Among the 16 patients with head and neck, thoracic, and abdominal/pelvic tumors, 2, 1, 12, and 1 cases developed complete response, partial response, stable disease, or disease progression, respectively. Progression-free survival rate was 93.8% (15/16). Among the 19 patients with prostate cancer, biological-recurrence free survival was 100%. Particle therapy was well tolerated in all 35 patients. Twenty-five patients (71.4%) experienced 33 grade 1 acute adverse effects, which subsided at 1 year follow-up. Six (17.1%) patients developed grade 1 late adverse effects. No significant change in ECOG or body weight was observed. Conclusions IONTRIS is safe and effective for clinical use. However, long term follow-up is needed to observe the late toxicity and long term result.

Objective To verify the safety and efficacy of IONTRIS particle therapy system ( IONTRIS) in clinical implementation. Methods Between 6.2014 and 8.2014, a total of 35 patients were enrolled into this trial:31 males and 4 females with a median age of 69 yrs ( range 39?80) . Ten patients had locally recurrent head and neck tumors after surgery, 4 cases with thoracic malignancies, 1 case with hepatocellular carcinoma, 1 case with retroperitoneal sarcoma, and 19 cases with non?metastatic prostate carcinomas. Phantom dose verification was mandatory for each field before the start of radiation. Results Twenty?two patients received carbon ion and 13 had proton irradiation. With a median follow?up time of 1 year, all patients were alive. Among the 16 patients with head and neck, thoracic, and abdominal/pelvic tumors, 2, 1, 12, and 1 cases developed complete response, partial response, stable disease, or disease progression, respectively. Progression?free survival rate was 93.8％ (15/16). Among the 19 patients with prostate cancer, biological?recurrence free survival was 100％. Particle therapy was well tolerated in all 35 patients. Twenty?five patients (71.4％) experienced 33 grade 1 acute adverse effects, which subsided at 1 year follow?up. Six ( 17.1％) patients developed grade 1 late adverse effects. No significant change in ECOG or body weight was observed. Conclusions IONTRIS is safe and effective for clinical use. However, long term follow?up is needed to observe the late toxicity and long term result.

Objective To verify the safety and efficacy of IONTRIS particle therapy system ( IONTRIS) in clinical implementation. Methods Between 6.2014 and 8.2014, a total of 35 patients were enrolled into this trial:31 males and 4 females with a median age of 69 yrs ( range 39?80) . Ten patients had locally recurrent head and neck tumors after surgery, 4 cases with thoracic malignancies, 1 case with hepatocellular carcinoma, 1 case with retroperitoneal sarcoma, and 19 cases with non?metastatic prostate carcinomas. Phantom dose verification was mandatory for each field before the start of radiation. Results Twenty?two patients received carbon ion and 13 had proton irradiation. With a median follow?up time of 1 year, all patients were alive. Among the 16 patients with head and neck, thoracic, and abdominal/pelvic tumors, 2, 1, 12, and 1 cases developed complete response, partial response, stable disease, or disease progression, respectively. Progression?free survival rate was 93.8％ (15/16). Among the 19 patients with prostate cancer, biological?recurrence free survival was 100％. Particle therapy was well tolerated in all 35 patients. Twenty?five patients (71.4％) experienced 33 grade 1 acute adverse effects, which subsided at 1 year follow?up. Six ( 17.1％) patients developed grade 1 late adverse effects. No significant change in ECOG or body weight was observed. Conclusions IONTRIS is safe and effective for clinical use. However, long term follow?up is needed to observe the late toxicity and long term result.

Objective To investigate the effectiveness of heart valve replacement in the same period of radiofrequency ablation in the treatment of atrial fibrillation.Methods Eighty-six patients with atrial fibrillation underwent heart valve replacement in the same period of bipolar radiofrequency ablation system according to the maze heart valve replacement operation principle.And optimized the operation method.Results No death occurred during operation.The average ablation time was (23 ± 8) minutes with a range of 16-56 minutes.Sinus rhythm of the heart was restored after surgery in all patients (100％).The long-term success rate was 98.8％ (85/86).Conclusion Our optimization of heart valve replacement in the same period of radiofrequency ablation enhanced the success rate of the operation,simplified the procedures,meanwhile it might need widely application clinically.